Patent application number | Description | Published |
20090010962 | Genetically Engineered Swine Influenza Virus and Uses Thereof - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 01-08-2009 |
20100150941 | HEMAGGLUTININ ANTIBODY AND USES THEREOF - Passive antibody therapy as a tool for both prophylaxis against—and treatment of—highly pathogenic H5N1 influenza virus, providing immediate immunity is described. It is provided by an antibody specific to hemagglutinin capable of neutralizing influenza viruses and methods of making and using the same, the methods and compounds described herein may be used in diagnostic, prophylactic and therapeutic methods. | 06-17-2010 |
20110104202 | Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency - The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines. | 05-05-2011 |
20130017216 | Modified Influenza Virus For Monitoring And Improving Vaccine Efficiency - The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines. | 01-17-2013 |
20130034581 | GENETICALLY ENGINEERED SWINE INFLUENZA VIRUS AND USES THEREOF - The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations. | 02-07-2013 |
20140030702 | MODIFIED INFLUENZA VIRUS FOR MONITORING AND IMPROVING VACCINE EFFICIENCY - The immunogenicity of the influenza virus hemagglutinin (HA) molecule may be increased by substitutions of amino acids in the HA sequence. The substitution of specific HA residues, such as asparagine at position 223 of H5 HA, increase the sensitivity of the hemagglutinin inhibition (HI) assay by altering receptor specificity and/or antibody-antigen binding. HA molecules containing such substitutions will be useful in the development of diagnostic reference viruses and improved influenza vaccines. | 01-30-2014 |